March 23rd 2023
The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.
February 28th 2023
Atezolizumab Does Not Demonstrate Significant OS Benefit Over Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial CancerFebruary 26th 2023
Atezolizumab did not yield a significant improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.
Pembrolizumab Shows Antitumor Activity at 45-Month Follow-Up in BCG-Unresponsive Papillary NMIBCFebruary 25th 2023
Patients with papillary high-risk non-muscle-invasive bladder cancer whose disease was BCG-unresponsive showed continued antitumor activity with pembrolizumab monotherapy.
Adjuvant Nivolumab Continues to Minimize Recurrence for Patients With Muscle-Invasive Urothelial CancerFebruary 21st 2023
Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.
Real-World Data Supports Front-Line Maintenance With Avelumab For Locally Advanced, Metastatic Urothelial CarcinomaFebruary 20th 2023
Real-world data support front-line maintenance with avelumab for patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy.
Long-Term Tolerability Reported With Darolutamide Use in Patients With Nonmetastatic CRPCFebruary 18th 2023
Approximately 30% of patients remained on treatment with darolutamide for over 4 years, according to a long-term safety and tolerability updated from the ARAMIS rollover study.
Talazoparib/Enzalutamide Improves Imaging-Based PFS in Metastatic CRPC, Regardless of HRR StatusFebruary 17th 2023
At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.
Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-EffectiveJanuary 18th 2023
A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.
Neoadjuvant Split-Dose Chemotherapy Represents Potential New Standard of Care for High-Risk UTUCJanuary 13th 2023
Neoadjuvant treatment with gemcitabine and split-dose cisplatin followed by surgical resection and lymph node dissection proved to be effective and well-tolerated for patients with high-risk upper tract urothelial carcinoma.
Enzalutamide Inspires Meaningful Delay in PSA Progression For Patients With PSA-Recurrent High-Risk Prostate CancerDecember 3rd 2022
Combining enzalutamide with salvage radiation therapy helped delay prostate-specific antigen progression in patients with PSA-recurrent, high-risk prostate cancer.
Rogaratinib May Be Effective for Patients With Bladder Cancer and FGFR3 DNA AlterationsNovember 14th 2022
Rogaratinib did not display a significant benefit over chemotherapy in patients with FGFR mutated bladder cancer, but the targeted treatment did generate encouraging responses among those with FGFR3 DNA alterations.
Adjuvant RCC Therapy Remains a Challenge as Treatment Landscape Continues to EvolveNovember 3rd 2022
Nancy Moldawer, RN, MSN, cochair of the Kidney Cancer Association's Clinical Advisory Board, speaks to unfolding data in the renal cell carcinoma space and the challenges in providing adjuvant therapy to this patient population.
Adding Cediranib to Olaparib Increases Treatment Efficacy, But Raises Toxicity Concerns, in mCRPCOctober 29th 2022
A regimen of cediranib and olaparib improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared with olaparib monotherapy. However, the rate of dose reductions was doubled with the combination.
Rucaparib Boosts Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate CancerOctober 7th 2022
The median radiographic progression-free survival (rPFS) was 11.2 months among patients with castration-resistant prostate cancer who received rucaparib. In the control arm, median rPFS was 6.4 months.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for PatientsSeptember 28th 2022
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Lenvatinib Dose Escalation Is Associated With Favorable Outcomes in Patients with HCCSeptember 21st 2022
In a real-world analysis of patients with hepatocellular carcinoma, the median overall survival with lenvatinib was 9.7 months in the low-dose group and 7.6 months in the recommended-dose group.
Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCCSeptember 19th 2022
Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting